PMID- 37962352
OWN - NLM
STAT- MEDLINE
DCOM- 20231205
LR  - 20231205
IS  - 1543-8392 (Electronic)
IS  - 1543-8384 (Linking)
VI  - 20
IP  - 12
DP  - 2023 Dec 4
TI  - Opportunities for Bioactive Glass in Gastrointestinal Conditions: A Review of 
      Production Methodologies, Morphology, Composition, and Performance.
PG  - 5954-5980
LID - 10.1021/acs.molpharmaceut.3c00188 [doi]
AB  - Bioactive glasses (BGs) are widely used in orthopedic and dental applications for 
      their ability to stimulate endogenous bone formation and regeneration. BG 
      applications more recently broadened to include soft tissue conditions, based on 
      their ability to stimulate angiogenesis, soft tissue regeneration, and wound 
      healing. Sol-gel synthesis has helped facilitate this expansion, allowing 
      formulators to tailor the morphological characteristics of the BG matrix. The 
      effectiveness of BGs in skin wound healing is viewed as a gateway for their use 
      as both a therapeutic and drug delivery platform in other soft tissue 
      applications, notably gastrointestinal (GI) applications, which form the focus of 
      this review. Recent changes in international guidelines for GI conditions shifted 
      clinical objectives from symptom management to mucosal wound healing. The 
      additional scrutiny of proton pump inhibitor (PPI) safety, increasing burden of 
      disease, and financial costs associated with gastroesophageal reflux disease 
      (GERD), peptic ulcer disease (PUD), and inflammatory bowel disease (IBD) open new 
      clinical possibilities for BG. This narrative literature review intersects 
      materials engineering, formulation science, and clinical practice, setting it 
      apart from prior literature. Broadly, current evidence for BG applications in GI 
      conditions is sparse and under-developed, which this review directly addresses. 
      It explores and synthesizes evidence that supports the potential use of 
      sol-gel-derived BG for the efficacious treatment of soft tissue applications, 
      with specific reference to GI conditions. An overview with comparative analysis 
      of current BG synthesis techniques and associated challenges is presented, and 
      influences of composition, biologically active ions, and morphological 
      characteristics in soft tissue applications are explored. To contextualize this, 
      sol-gel-derived BGs are proposed as a dual, tailorable therapeutic and drug 
      delivery platform for upper and lower GI conditions. Future directions for this 
      largely untapped area of translational research are also proposed, based on 
      extant literature.
FAU - Harrop, Angus C F
AU  - Harrop ACF
AUID- ORCID: 0000-0002-8278-304X
AD  - The University of Queensland, School of Pharmacy, The Pharmacy Australia Centre 
      of Excellence, 20 Cornwall St, Woolloongabba, Queensland 4102, Australia.
FAU - Tupally, Karnaker R
AU  - Tupally KR
AD  - The University of Queensland, School of Pharmacy, The Pharmacy Australia Centre 
      of Excellence, 20 Cornwall St, Woolloongabba, Queensland 4102, Australia.
FAU - Pandey, Preeti
AU  - Pandey P
AD  - The University of Queensland, School of Pharmacy, The Pharmacy Australia Centre 
      of Excellence, 20 Cornwall St, Woolloongabba, Queensland 4102, Australia.
FAU - Parekh, Harendra S
AU  - Parekh HS
AUID- ORCID: 0000-0001-8792-4318
AD  - The University of Queensland, School of Pharmacy, The Pharmacy Australia Centre 
      of Excellence, 20 Cornwall St, Woolloongabba, Queensland 4102, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231114
PL  - United States
TA  - Mol Pharm
JT  - Molecular pharmaceutics
JID - 101197791
RN  - 0 (Biocompatible Materials)
SB  - IM
MH  - *Wound Healing
MH  - *Osteogenesis
MH  - Glass
MH  - Biocompatible Materials
OTO - NOTNLM
OT  - bioactive glass
OT  - gastrointestinal
OT  - gastrointestinal reflux disease
OT  - inflammatory bowel disease
OT  - soft tissue wound healing
OT  - sol-gel
EDAT- 2023/11/14 12:43
MHDA- 2023/12/05 12:43
CRDT- 2023/11/14 09:04
PHST- 2023/12/05 12:43 [medline]
PHST- 2023/11/14 12:43 [pubmed]
PHST- 2023/11/14 09:04 [entrez]
AID - 10.1021/acs.molpharmaceut.3c00188 [doi]
PST - ppublish
SO  - Mol Pharm. 2023 Dec 4;20(12):5954-5980. doi: 10.1021/acs.molpharmaceut.3c00188. 
      Epub 2023 Nov 14.